Entering text into the input field will update the search result below

EPP: Pacific Ex Japan ETF With Consistent, Decent Yield, Nothing Exciting

Summary

  • iShares MSCI Pacific ex Japan ETF invests in mature companies in mature sectors within mature markets, hence its yield has been consistent and decent within a range of 3.6% to 4.8%.
  • EPP’s major investments in financial, materials, and energy sectors (58% of total) generated significantly high price growth during the past 12 months.
  • EPP’s portfolio has a weighted average price P/E ratio of 14.6, is currently trading almost at par, and its portfolio lacks clear outperformance potential.
  • Once the impact of the Russia-Ukraine conflict is gone, stocks within materials and energy sectors should grow at a much more stable but lower rate.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Tokyo city in Japan

StockByM

~ by Snehasish Chaudhuri, MBA (Finance).

iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP) is an exchange-traded large-cap/ value fund ("ETF") that invests in diversified stocks in public equity markets of Asia/Pacific developed regions. The fund uses representative sampling techniques to

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-


Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 



This article was written by

Avisol Capital Partners profile picture
16.85K Followers
Cautious, low key, disciplined investing in biopharma stocks
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research

Disclaimer - we are not investment advisors.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments

Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.